Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial

AIMS: In the CHAMPION PHOENIX trial, the potent, rapidly acting, intravenous platelet adenosine diphosphate receptor antagonist cangrelor reduced the 48-h incidence of major adverse cardiac events (MACE; death, myocardial infarction, stent thrombosis, or ischaemia-driven revascularization) compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Stone, Gregg W, Généreux, Philippe, Harrington, Robert A, White, Harvey D, Gibson, C Michael, Steg, P Gabriel, Hamm, Christian W, Mahaffey, Kenneth W, Price, Matthew J, Prats, Jayne, Deliargyris, Efthymios N, Bhatt, Deepak L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284164/
https://www.ncbi.nlm.nih.gov/pubmed/30203006
http://dx.doi.org/10.1093/eurheartj/ehy562

Ejemplares similares

Ejemplares similares